RxDoctor Payments Data

Dustin Debourge

Gerontology · Columbia, MONPI 1720688914

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Viiv Healthcare Company at 43.6% of the total.

$2,332in general payments, 2019–2025

Across 78 payments — averaging $29.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Gilead$642
  • Merck$194
  • AbbVie$143
  • Neurocrine Biosciences, Inc.$138
  • Actelion Pharmaceuticals US, Inc.$91
  • plus $108 from 5 others

What the payments were for

  • Food & beverage$2,332100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,332 in reported general payments places this provider in the 85th percentile of 175 gerontology providers in Missouri.

See all gerontology providers in Missouri

Medicare billing

Part B allowed, 2024
$15,660
Medicare patients
97
Services billed
270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala23$92,487
EliquisApixaban32$19,114
JardianceEmpagliflozin22$10,267
JanuviaSitagliptin Phosphate12$6,788
MyrbetriqMirabegron12$4,853
Incruse ElliptaUmeclidinium Bromide12$4,178
Memantine Hcl21$1,977
Tolterodine Tartrate24$1,922
Repaglinide11$1,572
Oxybutynin Chloride ErOxybutynin Chloride20$1,393
Memantine Hcl ErMemantine Hcl16$1,262
Olmesartan Medoxomil21$1,218
Atorvastatin Calcium66$1,187
Mirtazapine55$999
Omeprazole54$927

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$642$92,48723 claims
MerckJanuvia$194$6,78812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 175 gerontology providers in Missouri.

Other gerontology in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →